RxDoctor Payments Data

William Ward, DO

Pulmonary Disease · Abington, PANPI 1023093432

Payments from drug & device makers

$4,426in general payments, 2019–2025

Across 30 payments — averaging $147.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Genentech USA, Inc.$74
  • GSK$69
  • AstraZeneca$47
  • Abiomed$45
  • Mallinckrodt Enterprises LLC$31
  • plus $189 from 11 others

What the payments were for

  • Travel & lodging$86420%
  • Food & beverage$54412%
  • Education$3,01868%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,426 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$117,875
Medicare patients
417
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$199,299
Trelegy ElliptaFluticasone/Umeclidin/Vilanter141$114,874
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr103$65,486
Breo ElliptaFluticasone/Vilanterol114$61,796
Spiriva HandihalerTiotropium Bromide38$31,767
Incruse ElliptaUmeclidinium Bromide46$23,321
SymbicortBudesonide/Formoterol Fumarate58$16,531
Spiriva RespimatTiotropium Bromide14$14,042
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,287
Fluticasone-SalmeterolFluticasone Propion/Salmeterol58$6,554
Arnuity ElliptaFluticasone Furoate19$6,283
Albuterol Sulfate HfaAlbuterol Sulfate175$6,074
Wixela InhubFluticasone Propion/Salmeterol29$4,118
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,968
AsmanexMometasone Furoate14$2,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$69$271,761423 claims
Boehringer IngelheimOfev, Spiriva Respimat$20$213,34127 claims
AstraZenecaSymbicort, Breztri Aerosphere$47$29,81879 claims
MerckAsmanex$25$2,90914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →